Toronto Dominion Bank Reduces Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Toronto Dominion Bank decreased its position in DexCom, Inc. (NASDAQ:DXCM) by 4.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 118,166 shares of the medical device company’s stock after selling 6,136 shares during the period. Toronto Dominion Bank’s holdings in DexCom were worth $16,390,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after acquiring an additional 136,282 shares in the last quarter. Capital Research Global Investors lifted its position in shares of DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC lifted its position in shares of DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after acquiring an additional 1,398,136 shares in the last quarter. Capital World Investors lifted its position in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after acquiring an additional 5,256,092 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its position in shares of DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after acquiring an additional 3,672,471 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 40.7 %

Shares of NASDAQ:DXCM traded down $43.85 on Friday, reaching $64.00. 53,844,273 shares of the company traded hands, compared to its average volume of 3,277,459. The business’s 50-day simple moving average is $115.28 and its 200 day simple moving average is $123.83. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market capitalization of $25.45 billion, a P/E ratio of 41.29, a price-to-earnings-growth ratio of 2.74 and a beta of 1.16. The company has a current ratio of 2.90, a quick ratio of 2.53 and a debt-to-equity ratio of 1.08.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the firm earned $0.34 earnings per share. The company’s revenue for the quarter was up 15.3% compared to the same quarter last year. As a group, equities analysts anticipate that DexCom, Inc. will post 1.78 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on DXCM shares. Wells Fargo & Company dropped their target price on DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $145.00 to $75.00 in a report on Friday. Oppenheimer decreased their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday. BTIG Research decreased their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday. Finally, UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a report on Friday. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $113.06.

Insider Activity

In other news, CFO Jereme M. Sylvain sold 745 shares of the firm’s stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $85,712.25. Following the transaction, the chief financial officer now directly owns 84,948 shares of the company’s stock, valued at $9,773,267.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, EVP Sadie Stern sold 427 shares of the stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the sale, the executive vice president now directly owns 75,877 shares in the company, valued at $8,729,648.85. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jereme M. Sylvain sold 745 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $85,712.25. Following the sale, the chief financial officer now owns 84,948 shares of the company’s stock, valued at $9,773,267.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,112 shares of company stock valued at $480,861. 0.30% of the stock is currently owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.